Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
PHASE1
The purpose of this study is to evaluate the safety and tolerability of IC8...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
PHASE2
The primary purpose of this study is to evaluate the efficacy and safety of...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
The purpose of the Phase 1 portion of this study was to determine the dose ...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damag...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
PHASE1
The purpose of this study is to assess the effect LY2603618 on a protein \[...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
PHASE1
This is an open-label study being conducted to determine the metabolism and...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
PHASE1
The primary objective of this study is to evaluate the safety and tolerabil...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.